RETRACTION : Ivermectin Synergizes Sorafenib in Hepatocellular Carcinoma via Targeting Multiple Oncogenic Pathways

Read full text
Cited by: 1

Abstract

Lu H. Zhou L. Zuo H. Le W. Hu J. Zhang T. Li M. Yuan Y. “Ivermectin Synergizes Sorafenib in Hepatocellular Carcinoma via Targeting Multiple Oncogenic Pathways.” Pharmacology Research & Perspectives 10 no. 3 2022: e00954. https://doi.org/10.1002/prp2.954. The above article, published online 14 May 2022 on Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor-in-Chief Professor Jennifer Martin, the British Pharmacological Society and John Wiley and Sons Ltd. The retraction has been agreed after concerns were raised that the Corresponding Author was not personally involved in the submission process, did not sign the Open Access Agreement, and did not review or approve the final version of the manuscript prior to submission. Additionally, the investigation uncovered evidence of duplication of several images and figures from previously published articles. The authors state that the conclusions of the article are otherwise unaffected.

Fields of Study & Subjects

Parasitic Diseases Research and Treatment Helminth infection and control Parasites and Host Interactions

Publication details

Journal / source
Pharmacology Research & Perspectives
Publisher
Wiley
Volume
14
Issue
1
Pages
e70222–e70222
Publication date
1 February 2026
Language
EN